Literature DB >> 18449514

Preparation of pH-sensitive, long-circulating and EGFR-targeted immunoliposomes.

Min-Jung Kim1, Hyo Jung Lee, In-Ah Lee, In-Young Kim, Sun-Kyung Lim, Hyun-Ah Cho, Jin-Seok Kim.   

Abstract

A long-circulating formulation of pH-sensitive liposomes (PSLs) with antibodies against epidermal growth factor receptor (EGFR) attached was designed, expecting an increase in binding and delivery of liposomes to the target cells including non-small cell lung cancer (NSCLC) cells. Physicochemical properties of the PSLs were measured by SEM and DLS. Leakage of a self-quenching fluorescent probe, calcein, from the liposome was studied for the evaluation of pH-sensitivity. Encapsulation efficiency of gemcitabine (an anti-cancer drug) in PSLs was about 67%. Average size of liposomes was 88 nm in diameter. The PSL of DOPE/CHEMS (6:4 molar ratio) formulation showed a dramatic pH-sensitivity at/around pH 5.5, whereas non-PSL of DPPC/Chol or PC/CHEMS formulation did not. Anti-proliferation effect of gemcitabine-encapsulating PSLs & Ab-PSLs in A549 cells was 2-fold higher than the free drug, which was further elucidated by the apoptosis of the cells by gemcitabine (approximately 10% apoptosis for PSL or Ab-PSL formulation vs. approximately 1% for free drug or non-PSL formulation) using FACS analysis. These data demonstrate delivery of gemcitabine to tumor cells can be improved by long-circulating PSLs or Ab-PSLs formulations in vitro.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18449514     DOI: 10.1007/s12272-001-1190-9

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  6 in total

1.  Core-shell nanoparticulate formulation of gemcitabine: lyophilization, stability studies, and in vivo evaluation.

Authors:  Deepak Chitkara; Anupama Mittal; Ram I Mahato; Neeraj Kumar
Journal:  Drug Deliv Transl Res       Date:  2014-12       Impact factor: 4.617

2.  Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes.

Authors:  Yingna He; Linhua Zhang; Cunxian Song
Journal:  Int J Nanomedicine       Date:  2010-09-20

Review 3.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

4.  Glucose-sensitive liposomes incorporating hydrophobically modified glucose oxidase.

Authors:  Seong-Min Jo; Hyeon Yong Lee; Jin-Chul Kim
Journal:  Lipids       Date:  2008-08-27       Impact factor: 1.880

5.  Complexes containing cationic and anionic pH-sensitive liposomes: comparative study of factors influencing plasmid DNA gene delivery to tumors.

Authors:  Yan Chen; Ji Sun; Ying Lu; Chun Tao; Jingbin Huang; He Zhang; Yuan Yu; Hao Zou; Jing Gao; Yanqiang Zhong
Journal:  Int J Nanomedicine       Date:  2013-04-22

Review 6.  State of the Art of Stimuli-Responsive Liposomes for Cancer Therapy.

Authors:  Elmira Heidarli; Simin Dadashzadeh; Azadeh Haeri
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.